Results 31 to 40 of about 60,523 (282)

Downregulation of PTEN mediates bleomycin-induced premature senescence in lung cancer cells by suppressing autophagy

Journal of International Medical Research, 2020
Objective Bleomycin is an important chemotherapeutic drug that activates premature senescence to decrease the tumorigenic process. We aimed to investigate the role of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in bleomycin-induced ...
Xiaoyan Sai, Chu Qin, Yan Wu, Yinying Zhao, Tao Bian   +4 more
doaj   +1 more source

Comparison of intralesional bleomycin with/without doxycycline in the primary management of pediatric lymphangiomas

Formosan Journal of Surgery, 2021
Background: Although surgical excision is the treatment of choice for lymphangiomas, recently many centers are practicing intralesional sclerotherapy as the primary modality. The purpose of this study was to review the efficacy of intralesional Bleomycin,
Naresh M Pawar, Aditya Pratap Singh, Arun Kumar Gupta, Vinita Chaturvedi, Dinesh Kumar Barolia   +4 more
doaj   +1 more source

Enhancement of bleomycin production in Streptomyces verticillus through global metabolic regulation of N-acetylglucosamine and assisted metabolic profiling analysis

Microbial Cell Factories, 2020
Background Bleomycin is a broad-spectrum glycopeptide antitumor antibiotic produced by Streptomyces verticillus. Clinically, the mixture of bleomycin A2 and bleomycin B2 is widely used in combination with other drugs for the treatment of various cancers.
Hong Chen, Jiaqi Cui, Pan Wang, Xin Wang, Jianping Wen   +4 more
doaj   +1 more source

The Effect of Artesunate on Bleomycin‑Induced Pulmonary Fibrosis

Acta Clinica Croatica
Despite new drug alternatives, no curative treatment for idiopathic pulmonary fibrosis (IPF) currently exists. This study aimed to evaluate the effects of artesunate on fibrosis, pulmonary hypertension, and inflammation-related changes in IPF.
Aysun Şengul, Oğuzhan Okutan, Bülent Altınsoy, Ceyda Anar, Onur Yazıcı, Fazilet Dede, Sibel Köktürk, Cüneyt Özer, Osman Fuat Sönmez, Gökhan Metin   +9 more
doaj   +1 more source

Flagellate dermatitis in a patient with testicular germ cell neoplasia on bleomycin

Dermatology Reports, 2023
Bleomycin, an antineoplastic antibiotic that inhibits DNA synthesis, is used to treat various malignant tumours such as Hodgkin's lymphoma, squamous cell carcinoma, and germ cell tumors.
Konstantina Mavridou, Aggeliki Karakasi, Evangeli Lampri, George Gaitanis, Ioannis D Bassukas   +4 more
doaj   +1 more source

Bleomycin-induced pulmonary fibrosis in mouse lungs.

, 2017
(A) Images of lungs from mice that were either subject to nasal administration of methylene blue (right) or not (left).
Yuko Yamada (3749758), Katsuko Sudo (222875), Masahiko Kuroda (142101), Masakatsu Takanashi (372895), Shinobu Ueda (52123), Shin-ichiro Ohno (3778615)   +5 more
core   +1 more source

Intralesional bleomycin for the treatment of periocular capillary hemangiomas

, 2012
ArticlePeriocular infantile capillary hemangiomas do not always respond well to conventional treatment modalities such as systemic or intralesional corticosteroids, radiotherapy or debulking surgery.
Smit D.P., Meyer D., Derrick P Smit, David Meyer, Meyer D, Smit DP   +5 more
core   +1 more source

Ploidy-Dependent Response to Anticancer Drugs of Human Embryonic Stem Cells. [PDF]

Cell Prolif
Using isogenic hESCs, differing only in their ploidy level, we show the effect of ploidy on the resistance to anticancer drugs. We demonstrate that polyploidy, by itself, confers sensitivity to chemotherapies, leading to higher apoptosis and delayed proliferation, while the loss of p53 reverses the phenotype, demonstrating higher resistance.
Haim-Abadi G, Benvenisty N.
europepmc   +2 more sources

Studies on the mechanism of action of the chemotherapeutic drug bleomycin on cell lines derived from haemangioma and keloid [PDF]

, 2009
Bleomycin has been used successfully in the treatment of haemangioma, keloid and vascular malformation; however the mode of action of this chemotherapeutic drug on these non-malignant dysplasias is not well understood.
Clarke, Lisa
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source